Michael Miller Net Worth

The estimated Net Worth of Michael Patrick Miller is at least $2.59 Milione dollars as of 12 August 2024. Mr. Miller owns over 23,358 units of Puma Biotechnology Inc stock worth over $117,500 and over the last 14 years he sold PBYI stock worth over $2,140,655. In addition, he makes $327,201 as Independent Director at Puma Biotechnology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Miller PBYI stock SEC Form 4 insiders trading

Michael has made over 53 trades of the Puma Biotechnology Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 23,358 units of PBYI stock worth $81,519 on 12 August 2024.

The largest trade he's ever made was selling 25,653 units of Puma Biotechnology Inc stock on 16 March 2022 worth over $71,828. On average, Michael trades about 2,358 units every 52 days since 2010. As of 12 August 2024 he still owns at least 47,000 units of Puma Biotechnology Inc stock.

You can see the complete history of Mr. Miller stock trades at the bottom of the page.

Michael Miller biography

Michael P. (Mike) Miller is Independent Director of the company. Mr. Miller has served as the Executive Vice President U.S. Commercial of Jazz Pharmaceuticals plc, a public biopharmaceutical company, since May 2017 and as its Senior Vice President U.S. Commercial from April 2014 until May 2017. From April 2010 to January 2014, Mr. Miller was Senior Vice President and Chief Commercial Officer of Vivus, Inc., a public biopharmaceutical company. From 2006 to 2010, Mr. Miller served as Vice President, Sales and Marketing, leading the HER Family Oncology Franchise, of Genentech, Inc., a biotechnology company and wholly owned subsidiary of Roche Holding Ltd. From 2003 to 2005, Mr. Miller served as the Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories, Inc. Previously, from 1997 to 2001, Mr. Miller served as Vice President of the Urology Business Unit of ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson. Prior to 1997, Mr. Miller served 13 years in various sales and marketing positions at Syntex Corporation, a pharmaceutical company acquired by Roche Holding Ltd. He currently serves as a member of two non-profit boards, the Leukemia and Lymphoma Society (Silicon Valley Chapter) and the Zane Beadles Parade Foundation. Mr. Miller received a B.S. in Business Administration and Finance from the University of San Francisco and an M.B.A. in Information and Computer Systems from San Francisco State University. Mr. Miller was nominated to serve as a director because of his significant experience and background in the life sciences industry.

What is the salary of Michael Miller?

As the Independent Director of Puma Biotechnology Inc, the total compensation of Michael Miller at Puma Biotechnology Inc is $327,201. There are 14 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.

How old is Michael Miller?

Michael Miller is 63, he's been the Independent Director of Puma Biotechnology Inc since 2018. There are 1 older and 13 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.

What's Michael Miller's mailing address?

Michael's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES, CA, 90024.

Insiders trading at Puma Biotechnology Inc

Over the last 12 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo e Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.

What does Puma Biotechnology Inc do?

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Complete history of Mr. Miller stock trades at Jazz Pharmaceuticals plc, Puma Biotechnology Inc, VIVUS e BioXcel Therapeutics Inc

Puma Biotechnology Inc executives and stock owners

Puma Biotechnology Inc executives and other stock owners filed with the SEC include:

• Alan H. Auerbach,
  Founder, Chairman, Pres, CEO & Sec.
• Jeffrey Jerome Ludwig,
  Chief Commercial Officer
• Alan Auerbach,
  Chairman of the Board, President, Chief Executive Officer
• Douglas Hunt B.Sc., FRAPS,
  Sr. VP of Regulatory Affairs, Medical Writing & Project Management
• Maximo F. Nougues,
  CFO & Principal Accounting Officer
• Douglas Hunt,
  Senior Vice President, Regulatory Affairs, Medical Writing and Project Management
• Richard Bryce,
  Chief Medical and Scientific Officer
• Ann Miller,
  Independent Director
• Dr. Richard P. Bryce,
  Chief Medical & Scientific Officer
• Maximo Nougues,
  Chief Financial Officer
• Hugh O Dowd,
  Independent Director
• Jay Moyes,
  Lead Independent Director
• Troy Wilson,
  Independent Director
• Adrian Senderowicz,
  Independent Director
• Michael Miller,
  Independent Director
• Mariann Ohanesian,
  IR Contact Officer
• Brian Stuglik,
  Director
• Dr. Alvin F. Wong,
  Chief Scientific Officer
• Charon Spencer Sr.,
  VP of HR
• Steven Lo,
  Chief Commercial Officer
• Capital Partners Gp, L.L.C....,
  
• Robert Charnas,
  
• Richard Benton Phillips,
  SEE REMARKS
• Charles R Eyler,
  SEE REMARKS
• Frank Zavrl,
  Director
• Thomas Malley,
  Director
• Jeffrey Jerome Ludwig,
  Chief Commercial Officer
• Alvin F Wong,
  Chief Scientific Officer
• Allison Dorval,
  Director
• Alessandra Cesano,
  Director